Create a narrative

Travere Therapeutics Community

NasdaqGM:TVTX Community

1 Narratives written by author
0 Comments on narratives written by author
24 Fair Values set on narratives written by author

Create a narrative

Travere Therapeutics

AN

AnalystConsensusTarget

Consensus Narrative from 14 Analysts

Expanded Approvals Will Broaden IgAN And FSGS Treatment Options

Key Takeaways FILSPARI's expanded approval and ongoing studies position it for increased revenue from treating renal diseases, with potential market expansion from the new sNDA submission for FSGS. Progress in the pegtibatinase program and possible REMS changes offer growth opportunities through new revenue streams and enhanced market penetration and retention.

US$33.67

FV

54.4% undervalued

47.99%

Revenue growth p.a.

0

0

8

8 days ago